Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasmacytoid dendritic cell | 18 studies | 44% ± 14% | |
microglial cell | 11 studies | 47% ± 17% | |
mucosal invariant T cell | 7 studies | 26% ± 12% | |
dendritic cell | 7 studies | 30% ± 12% | |
mast cell | 7 studies | 22% ± 4% | |
GABAergic neuron | 6 studies | 39% ± 19% | |
CD4-positive, alpha-beta T cell | 5 studies | 29% ± 9% | |
macrophage | 5 studies | 24% ± 8% | |
plasma cell | 4 studies | 24% ± 5% | |
CD16-negative, CD56-bright natural killer cell, human | 4 studies | 29% ± 15% | |
T cell | 4 studies | 27% ± 5% | |
glutamatergic neuron | 4 studies | 40% ± 15% | |
fibroblast | 4 studies | 22% ± 7% | |
club cell | 4 studies | 23% ± 9% | |
innate lymphoid cell | 4 studies | 32% ± 19% | |
interneuron | 4 studies | 41% ± 16% | |
conventional dendritic cell | 3 studies | 42% ± 22% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 26% ± 8% | |
group 3 innate lymphoid cell | 3 studies | 29% ± 10% | |
lymphocyte | 3 studies | 32% ± 11% | |
endothelial cell | 3 studies | 32% ± 16% | |
leukocyte | 3 studies | 45% ± 8% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 6 studies | 31% ± 16% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 99% | 745.07 | 575 / 578 | 92% | 7.98 | 1062 / 1155 |
prostate | 98% | 1371.68 | 241 / 245 | 81% | 3.72 | 409 / 502 |
thymus | 98% | 563.40 | 642 / 653 | 80% | 8.46 | 484 / 605 |
breast | 86% | 578.99 | 395 / 459 | 92% | 10.22 | 1031 / 1118 |
uterus | 98% | 547.15 | 167 / 170 | 79% | 7.40 | 363 / 459 |
skin | 100% | 1522.61 | 1805 / 1809 | 72% | 5.81 | 340 / 472 |
intestine | 100% | 1074.16 | 962 / 966 | 71% | 4.22 | 376 / 527 |
ovary | 97% | 579.32 | 175 / 180 | 73% | 5.43 | 315 / 430 |
stomach | 88% | 408.15 | 316 / 359 | 76% | 4.70 | 216 / 286 |
bladder | 81% | 840.90 | 17 / 21 | 78% | 6.96 | 393 / 504 |
kidney | 92% | 354.63 | 82 / 89 | 63% | 3.34 | 568 / 901 |
esophagus | 54% | 176.13 | 777 / 1445 | 89% | 8.42 | 163 / 183 |
pancreas | 21% | 51.77 | 70 / 328 | 93% | 9.09 | 166 / 178 |
brain | 59% | 171.53 | 1568 / 2642 | 42% | 1.88 | 295 / 705 |
adrenal gland | 81% | 212.37 | 209 / 258 | 19% | 0.96 | 44 / 230 |
spleen | 100% | 794.75 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 91% | 5.27 | 41 / 45 |
adipose | 88% | 379.35 | 1062 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 87% | 391.35 | 1164 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 80% | 572.89 | 744 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 76% | 4.18 | 22 / 29 |
heart | 33% | 86.17 | 283 / 861 | 0% | 0 | 0 / 0 |
muscle | 33% | 98.12 | 261 / 803 | 0% | 0 | 0 / 0 |
liver | 11% | 20.42 | 24 / 226 | 5% | 0.37 | 21 / 406 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0042475 | Biological process | odontogenesis of dentin-containing tooth |
GO_0050673 | Biological process | epithelial cell proliferation |
GO_0007224 | Biological process | smoothened signaling pathway |
GO_0030097 | Biological process | hemopoiesis |
GO_0002051 | Biological process | osteoblast fate commitment |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0001649 | Biological process | osteoblast differentiation |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0002062 | Biological process | chondrocyte differentiation |
GO_0032332 | Biological process | positive regulation of chondrocyte differentiation |
GO_0045879 | Biological process | negative regulation of smoothened signaling pathway |
GO_2000648 | Biological process | positive regulation of stem cell proliferation |
GO_0072089 | Biological process | stem cell proliferation |
GO_0001958 | Biological process | endochondral ossification |
GO_0045669 | Biological process | positive regulation of osteoblast differentiation |
GO_0035115 | Biological process | embryonic forelimb morphogenesis |
GO_1904383 | Biological process | response to sodium phosphate |
GO_0002063 | Biological process | chondrocyte development |
GO_0030509 | Biological process | BMP signaling pathway |
GO_0030217 | Biological process | T cell differentiation |
GO_0030182 | Biological process | neuron differentiation |
GO_0060395 | Biological process | SMAD protein signal transduction |
GO_0036076 | Biological process | ligamentous ossification |
GO_0050679 | Biological process | positive regulation of epithelial cell proliferation |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0045595 | Biological process | regulation of cell differentiation |
GO_0042487 | Biological process | regulation of odontogenesis of dentin-containing tooth |
GO_0030282 | Biological process | bone mineralization |
GO_0048701 | Biological process | embryonic cranial skeleton morphogenesis |
GO_0010467 | Biological process | gene expression |
GO_0040036 | Biological process | regulation of fibroblast growth factor receptor signaling pathway |
GO_0001503 | Biological process | ossification |
GO_0048863 | Biological process | stem cell differentiation |
GO_0030278 | Biological process | regulation of ossification |
GO_0048469 | Biological process | cell maturation |
GO_0002076 | Biological process | osteoblast development |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005667 | Cellular component | transcription regulator complex |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0043425 | Molecular function | bHLH transcription factor binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0019904 | Molecular function | protein domain specific binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0005524 | Molecular function | ATP binding |
GO_0031490 | Molecular function | chromatin DNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | RUNX2 |
Protein name | Truncated core binding factor alpha1 Alternative protein RUNX2 Runt-related transcription factor RUNX2 protein Runt-related transcription factor 2 (Acute myeloid leukemia 3 protein) (Core-binding factor subunit alpha-1) (CBF-alpha-1) (Oncogene AML-3) (Osteoblast-specific transcription factor 2) (OSF-2) (Polyomavirus enhancer-binding protein 2 alpha A subunit) (PEA2-alpha A) (PEBP2-alpha A) (SL3-3 enhancer factor 1 alpha A subunit) (SL3/AKV core-binding factor alpha A subunit) RUNX family transcription factor 2 |
Synonyms | PEBP2A OSF2 CBFA1 AML3 |
Description | FUNCTION: Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis . Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE) (By similarity). Inhibits KAT6B-dependent transcriptional activation. . FUNCTION: Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. . |
Accessions | I3L354 U3RG86 ENST00000371432.7 [Q13950-3] ENST00000483377.5 A0A0D9SEN7 ENST00000646519.1 ENST00000359524.7 [Q13950-2] ENST00000478660.6 I3L4L9 Q13950 ENST00000576263.5 ENST00000647337.2 [Q13950-1] ENST00000625924.1 L8E7D8 I3L0L0 ENST00000371438.5 [Q13950-1] ENST00000371436.10 [Q13950-3] A0A2R8Y7Z3 Q32MY8 |